Valbiotisannounces the "broad success" of a Phase II/III clinical trial with TOTUM63, conforming the efficacy of this treatment in type 2 diabetes on the criterion of reducing fasting glycemia to 2 and 3 intakes per day.

According to Sébastien Peltier, co-founder and Chairman of Valbiotis' Executive Committee, the results of this study represent 'a major advance in the fight against diabetes and its complications for untreated (early-stage) type 2 diabetics and pre-diabetics'.

We have provided unequivocal clinical proof that TOTUM63 is a promising solution for millions of people worldwide, helping to prevent progression to type 2 diabetes", he adds.

These positive results trigger a lump-sum payment of 4 million Swiss francs from Nestlé Health Science as part of the overall strategic partnership.

This payment will be made on delivery of the full study report during the summer.

Copyright (c) 2023 CercleFinance.com. All rights reserved.